The pharmacotherapy of heparin-induced thrombocytopenia (HIT): A review of contemporary therapeutic challenges in clinical practice

Malaysian Journal of Medical Sciences

Volumn 15, Issue 2, 2008, Pages 3-13

  Hassan, Yahaya ^a   Awaisu, Ahmed ^a   Al Meman, Ahmad Abdul Rahman ^a   Aziz, Noorizan Abd ^a  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

Author keywords

Argatroban; Bivalirudin; Danaparoid; Drotrecogin alfa (activated); Fondaparinux; Heparin induced thrombocytopenia; HIT; Lepirudin; Therapeutics

Indexed keywords

ARGATROBAN; ARIXTA; DANAPAROID; DROTRECOGIN; FONDAPARINUX; HEPARIN; HIRULOG; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG; WARFARIN;

AGE DISTRIBUTION; ANTICOAGULANT THERAPY; BLOOD CLOTTING TIME; CLINICAL FEATURE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; IMMUNOPATHOGENESIS; INCIDENCE; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE THERAPY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; PREVALENCE; RACE DIFFERENCE; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SEROLOGY; SEX DIFFERENCE; THROMBOSIS PREVENTION;

EID: 70349504345     PISSN: 1394195X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121: 535-55.
2. Warkentin TE. Heparin-induced thrombocytopenia. Dis Mon 2005; 51: 141-49.
3. Dager WE, White RH. Treatment of heparin-induced thrombocytopenia. Ann Pharmacother 2002; 36: 489-503.
4. Thong CL, Kam PCA. Heparin-induced thrombocytopenia. Current Anaesthesia & Critical Care 2005; 16: 143-50.
5. Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thrombosis Research 2006; 118: 165-76.
6. DuBose J, Sutherland M, Moulton M, et al. Heparin-induced thrombocytopenia and thrombosis syndrome after cardiac surgery. Current surgery 2004; 61(2): 209-11.
7. Papadopoulos S, Flynn JD, Lewis DA. Fondaparinux as a treatment option for heparin-induced thrombocytopenia. Pharmacotherapy 2007; 27(6): 921-26.
8. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic therapy. Chest 2004; 126: 311S-337S.
9. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Eng J Med 2006; 355: 809-17.
10. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large tertiary care, teaching hospital. Chest 2007; 131: 1644-49.
11. Hutchison CA, Dasgupta I. National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK. Nephrol Dial Transplant 2007; 22: 1680-84.
12. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005; 94(1):132-5.
13. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006; 108(9): 2937-41.
14. Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 2006; 129(6):1407-16.
15. Creekmore FM, Oderda GM, Pendleton RC, Brixner DI. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy 2006; 26(10): 1438-45.
16. Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998; 101(4): 653-55.
17. Bauer TL, Arepally G, Konkle BA et al. Prevalence of heparin-associated antibodies without thombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997; 95: 1242-46.
18. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007; 35(4): 1165-76.
19. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003; 101(8): 2955-59.
20. Hoh BL, Aghi M, Pryor JC, Ogilvy CS. Heparin-induced thrombocytopenia Type II in subarachnoid hemorrhage patients: incidence and complications. Neurosurgery 2005; 57(2): 243-8.
21. Risch L, Huber AR, Schmugge M. Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children. Thromb Res 2006; 118(1): 123-35.
22. Klenner AF, Lubenow N, Raschke R, Greinacher A. Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thromb Haemost 2004; 91(4): 719-24.
23. Opatrny L, Warner MN. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol 2004; 76(3): 240-4.
24. Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy 2007; 27(4): 564-87.
25. Ahmad S. Heparin-induced thrombocytopenia: impact of bovine versus porcine heparin in HIT pathogenesis. Front Biosci 2007; 12: 3312-20.
26. Serebruany MV, Malinin AI, Serebruany VL. Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives. Expert Opin Pharmacother 2006; 7(1): 81-9.
27. Harenberg J, Jorg I, Fenyvesi T, Piazolo L. Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban. J Thromb Thrombolysis 2005; 19(1): 65-9.
28. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. New Eng J Med 2000; 344(7): 1286-92.
29. Menajovsky LB. Heparin-induced thrombocytopenia: clinical manifestation and management strategies. Am J Medic 2005; 118(8A): 21S-30S.
30. Davidson SJ, Wadham P, Rogers L, Burman JF. Endothelial cell damage in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 2007; 18(4): 317-20.
31. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of anti-PF4/ heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007; 5(8): 1666-73.
32. Tardy B, Tardy-Poncet B, Fournel P, Venet C, Jospe R, Dacosta A. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost 1999; 82(3): 1199-200.
33. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Third Edition, Warkentin TE, Greinacher A (Eds). New York, Marcel Dekker, 2004, pp53-106.
34. Bakaeen FG, Walkes JC, Reardon MJ. Heparin-induced thrombocytopenia associated with bilateral adrenal hemorrhage after coronary artery bypass surgery. Ann Thorac Surg 2005; 79(4): 1388-90.
35. Smythe MA, Stephens JL, Mattson JC. Delayed-onset heparin-induced thrombocytopenia. Ann Emerg Med 2005; 45: 417-19.
36. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002; 136: 210-15.
37. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2: 148-57.
38. Lo GK, Warkentin TE. Preliminary evaluation of a clinical scoring system for estimating the pretest probability of heparin-induced thrombocytopenia: the "4 T's". Blood 2003; 102 (suppl 1): 535a.
39. Seybert AL, Coons JC, Zerumsky K. Treatment of HIT: Is there a role for bivalirudin? Pharmacotherapy 2006; 26(2): 229-41.
40. Knoderer CA, Knoderer HM, Turrentine MW, and Kumar M. Lepirudin anticoagulation for heparin-induced thrombocytopenia after cardiac surgery in a pediatric patient. Pharmacotherapy 2006; 26(5): 709-12.
41. Taylor LM, Smith KM. The paradox of heparin-induced thrombocytopenia: future anticoagulation. Orthopedics 2005; 28(7): 651-54.
42. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106: 629-35.
43. Naranjo CA, Busto U, Sellers EM, et al. A Method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
44. Warkentin TE and Barkin RL. Newer strategies for the treatment of heparin-induced thrombocytopenia. Pharmacotherapy 1999; 19(2): 181-95.
45. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene complicating heparin-induced thrombocytopenia (abstr). Ann Intern Med 1997; 127: 804-12.
46. Gruel Y, Pouplard C, Nguyen P, et al. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol 2003; 121(5): 786-92.
47. Hassell K. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy. Chest 2005; 127(2): 1S-8S.
48. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary interventions: a report of the ACCP/AHA task force on practice guidelines. Circulation 2006; 113: 156-75.
49. Chen JL. Argatroban: a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications. Heart Dis 2001; 3(3): 189-98.
50. Tokuda Y, Matsumoto M, Sugita T, et al. Vascular surgery using argatroban in a patient with a history of heparin-induced thrombocytopenia. Circ J 2003; 67(10): 889-90.
51. Mejak B, Giacomuzzi C, Heller E, et al. Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia. J Extra Corpor Technol 2004; 36(2): 178-81.
52. Matthai WH, Jr. Safety and efficacy of argatroban in patients with heparin-induced thrombocytopenia. Curr Hematol Rep 2006; 5(1): 95-9.
53. GlaxoSmithKline. Argatroban injection prescribing information. Research Triangle Park, NC; 2005.
54. Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy 2005; 25(12): 1736-45.
55. Verme-Gibboney CN, Hursting MJ. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2003; 37(7-8): 970-5.
56. Pendleton R, Wheeler MM, Rodgers GM. Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome. Ann Pharmacother 2006; 40(5): 972-6.
57. Reddy BV, Grossman EJ, Trevino SA, Hursting MJ, Murray PT. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.Ann Pharmacother 2005; 39(10): 1601-5.
58. Guzzi LM, McCollum DA, Hursting MJ. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 2006; 22(3): 169-76.
59. Tang IY, Cox DS, Patel K, et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2005; 39(2): 231-6.
60. Lau KK. Use of argatroban for hemodialysis and continuous veno-veno hemodialysis in a patient with heparin-induced thrombocytopenia: case summary. Hemodialysis Intern 2005; 9(1): 101.
61. Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006; 129(5): 1167-75.
62. Murphy GS, Marymont JH. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2007; 21(1): 113-26.
63. Gasparovic H, Nathan NS, Fitzgerald D, Aranki SF. Severe argatroban-induced coagulopathy in a patient with a history of heparin-induced thrombocytopenia. Ann Thorac Surg 2004; 78(6): e89-91.
64. Lewis BE, Matthai WH, Jr., Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002; 57(2): 177-84.
65. Sakai K, Oda H, Honsako A, Takahashi K, Miida T, Higuma N. Obstinate thrombosis during percutaneous coronary intervention in a case with heparin-induced thrombocytopenia with thrombosis syndrome successfully treated by argatroban anticoagulant therapy. Catheter Cardiovasc Interv 2003; 59(3): 351-4.
66. Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003; 37(5): 652-4.
67. Ichikawa M, Oue M, Okamoto A, et al. A case of heparin-induced thrombocytopenia associated with unexpected excessive argatroban anticoagulation after abdominal aortic aneurysm resection. Masui 2006; 55(2): 188-92.
68. LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 2004; 32(4): 976-80.
69. Potter KE, Raj A, Sullivan JE. Argatroban for anticoagulation in pediatric patients with heparin-induced thrombocytopenia requiring extracorporeal life support. J Pediatr Hematol Oncol 2007; 29(4):265-8.
70. Scott LK, Grier LR, Conrad SA. Heparin-induced thrombocytopenia in a pediatric patient receiving extracorporeal support and treated with argatroban. Pediatr Crit Care Med 2006; 7(3): 255-7.
71. Boshkov LK, Ibsen A, Kirby A, Ungerleider R, Shen I. Report of argatroban infusions for heparin-induced thrombocytopenia diagnosed by functional assay in 2 congenital cardiac surgery patients, a neonate and a 5-month old. J Thromb Haemost 2003; 1(Suppl.1): 1495.
72. Boshkov LK, Ibsen A, Kirby A, Ungerleider R, Shen I. Heparin-induced thrombocytopenia in neonates and very young children undergoing congenital cardiac surgery: a likely under-recognized complication with significant morbidity and mortality: report of 4 sequential cases. J Thromb Haemost 2003; 1(Suppl.1): 1494.
73. John TE, Hallisey RK, Jr. Argatroban and lepirudin requirements in a 6-year-old patient with heparin-induced thrombocytopenia. Pharmacotherapy 2005; 25(10): 1383-8.
74. Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated HIT: an analysis of 3 prospective studies. Blood 2004; 104: 3072-77.
75. Berlex. Refludan [lepirudin (rDNA) for injection] prescribing information. Wayne, NJ; 2004.
76. Mahaffey KW, Lewis BE, Wildermann NM, et al. Anticoagulant therapy with bivalirudin to assist in the performance of PCI in patients with HIT (ATBAT) study: main results. J Invasive Cardiol 2003; 15: 611-16.
77. Spinler SA. New concepts in heparin - induced thrombocytopenia: diagnosis and management. J Thromb Thrombolysis 2006; 21(1): 17-21.
78. Franchini M. Heparin-induced thrombocytopenia: an update. Thrombosis Journal 2005; 3: 14. DOI: 10.1186/1477-9560-3-14.
79. Taylor LM, Smith KM. The paradox of heparin-induced thrombocytopenia: the initial management. Orthopedics 2005b; 28(6): 559-62.
80. Glaxosmithkline. Arixta® (Fondaparinux sodium) injection prescribing information. Research Triangle Park, NC; 2005.
81. Elalamy I. Absence of in vitro cross-reaction of pentasaccharide with plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia [Letter]. Thromb Haemost 1995; 74(5): 1384-85.
82. Amiral J, Lormeau JC, Marfaing-koka AM, et al. Absence of cross-reactivity of SR90107A/ORG 3140 petasaccharide with antibodies to heparin-PF4 complexes developed in HIT. Blood Coagul Fibrinolysis 1997; 8: 114-17.
83. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105(1): 139-44.
84. Bradner J, Hallisey RK, Kuter DJ. Fondaparinux in the treatment of heparin- induced thrombocytopenia [abstract]. Blood 2004; 104: 569.
85. Kovacs MJ. Successful treatment of heparin-induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005; 93: 999-1000.
86. Warkentin TE, Cook RJ, Marder VJ, et al. Antiplatelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106: 3791-96.
87. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Eng J Med 2007; 356(25): 2653.
88. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
89. Rubeiz GJ, Marrone CM, Leclere JR. Treatment of heparin-induced thrombocytopenia with drotrecogin alfa (activated). Pharmacotherapy 2006; 26(3): 428-34.
90. Rubeiz GJ, Marrone Cm, Leclare JR. Treatment of heparin-induced thromboytopemia with drotrecogin alfa (activated). Pharmacotherapy 2006; 26(3): 428-34.